UniSa - IRIS Institutional Research Information System

MASARONE, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.431
AS - Asia 1.388
EU - Europa 1.294
SA - Sud America 272
AF - Africa 20
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 5
Totale 6.415
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.398
SG - Singapore 517
CN - Cina 421
IT - Italia 335
RU - Federazione Russa 270
BR - Brasile 251
UA - Ucraina 179
DE - Germania 138
IE - Irlanda 121
TR - Turchia 115
VN - Vietnam 112
KR - Corea 97
FI - Finlandia 60
HK - Hong Kong 55
SE - Svezia 55
FR - Francia 27
GB - Regno Unito 26
CA - Canada 25
DK - Danimarca 25
NL - Olanda 18
IN - India 14
AT - Austria 11
BD - Bangladesh 10
AR - Argentina 9
CZ - Repubblica Ceca 7
UZ - Uzbekistan 7
IQ - Iraq 6
AE - Emirati Arabi Uniti 5
EC - Ecuador 5
EU - Europa 5
MX - Messico 5
PK - Pakistan 5
PL - Polonia 5
ZA - Sudafrica 5
AU - Australia 4
ES - Italia 4
GR - Grecia 4
JP - Giappone 4
MA - Marocco 4
EG - Egitto 3
TN - Tunisia 3
VE - Venezuela 3
CO - Colombia 2
HN - Honduras 2
IR - Iran 2
KE - Kenya 2
LT - Lituania 2
MY - Malesia 2
NP - Nepal 2
PS - Palestinian Territory 2
PY - Paraguay 2
RO - Romania 2
TW - Taiwan 2
AL - Albania 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
DZ - Algeria 1
GA - Gabon 1
GE - Georgia 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
QA - Qatar 1
SA - Arabia Saudita 1
UG - Uganda 1
Totale 6.415
Salva come PNG Salva come JPEG
Città #
Ann Arbor 778
Chandler 360
Princeton 344
Woodbridge 334
Jacksonville 263
Houston 172
Singapore 148
Ashburn 141
Beijing 118
Dublin 118
Dong Ket 106
Izmir 106
Wilmington 102
Moscow 72
Nanjing 72
Andover 63
Hong Kong 53
Munich 52
Pellezzano 44
Boardman 42
Naples 35
The Dalles 28
Fairfield 27
Salerno 27
Redwood City 26
São Paulo 24
Changsha 23
Hebei 23
Norwalk 23
Shenyang 22
Turku 22
Columbus 19
Washington 19
Jinan 17
Nanchang 17
Dearborn 16
Los Angeles 16
Dallas 14
Jiaxing 14
Nuremberg 13
Belo Horizonte 12
Council Bluffs 12
Tianjin 12
Copenhagen 11
Seattle 11
Fisciano 10
Jinju 10
Milan 10
Nürnberg 10
Amsterdam 9
Guangzhou 9
Helsinki 9
London 9
Maletto 9
Ottawa 9
Pontecagnano 9
Cambridge 8
Haikou 8
New York 8
Rio de Janeiro 8
San Diego 8
Zhengzhou 8
Düsseldorf 7
Edmonton 7
Rome 7
Tashkent 7
Falls Church 6
Lappeenranta 6
San Mango Piemonte 6
Santa Clara 6
Mestre 5
Montreal 5
Pune 5
Brasília 4
Brno 4
Brooklyn 4
Dhaka 4
Frederiksberg 4
Fuzhou 4
Johannesburg 4
Kunming 4
Napoli 4
Pompei 4
Porto Alegre 4
Raleigh 4
Redmond 4
Saint Petersburg 4
Simi Valley 4
Warsaw 4
Wuhan 4
Athens 3
Baghdad 3
Betim 3
Bolzano 3
Boston 3
Caiazzo 3
Contagem 3
Daejeon 3
Falkenstein 3
Hanoi 3
Totale 4.287
Salva come PNG Salva come JPEG
Nome #
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 137
Diaphragmatic motility assessment in COPD exacerbation, early detection of Non-Invasive Mechanical Ventilation failure: a pilot study 134
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 125
HIGH PREVALENCE OF HEPATITIS C (HCV) INFECTION AND FAVORABLE PROGNOSIS IN PRIMARY HEPATIC LYMPHOMA (PHL) 119
Coeliac disease and C virus-related chronic hepatitis: a non association 116
"Non alcoholic fatty liver disease and eNOS dysfunction in humans" 112
Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment 111
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 108
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells 108
Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 106
Alcoholic Liver Disease and Hepatitis C Chronic Infection 102
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage 98
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease 96
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. 94
Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients 93
[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP) 93
Antiviral therapy: Why does it fail in HCV-related chronic hepatitis? 93
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 87
Pharmacotherapy of alcoholic liver disease in clinical practice 84
507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues 84
Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563] (DOI:10.1016/j.jhep.2008.06.025) 84
Epidemiology and Natural History of Alcoholic Liver Disease 83
Lung ultrasound for diagnosis of pneumonia in emergency department 80
Impact of telaprevir in HCV patients with cirrhosis and RVR: Real-life data from boceprevir or telaprevir based “triple therapy” experience in southern Italy 80
The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction 79
Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy 79
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. 78
FN 44 HEPATIC RETINOL BINDING PROTEIN 4 (RBP-4) LEVELS ARE SIGNIFICANTLY RELATED TO THE STEATOHEPATITIS GRADE (COMPROMISSION) BUT NOT WITH HCV INFECTION 78
Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: Results of a prospective multicentric study 78
442 TNF-alpha and IL-10 genetic polymorphisms influence the natural history and the response to antiviral therapy in HCV related chronic hepatitis 76
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease 76
Inferior vena cava collapsibility to guide fluid removal in slow continuous ultrafiltration: A pilot study 74
Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus 74
Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. 72
Non Alcoholic Fatty Liver: Epidemiology and Natural History 72
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. 71
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. 70
Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 69
Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets 69
HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 68
Interference of diet on liver histology and on the response to interferon therapy in patients with HCV-related chronic liver disease 67
Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. 67
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 67
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease 66
Evaluation of allelic frequency and genetic risk score of non-alcoholic fatty liver disease in a population of Southern Italy 65
Adiponectin in hepatology 64
P. 253 Rapid virological response in genotype 1b patients treated with peginterferon plus ribavirin: evidence for a significant sustained virological response (SVR) after 24 weeks of therapy in peg-interferon-alpha-2a treated patients 63
Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based "triple therapy" experience in southern Italy 63
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease 63
The diagnostic conundrum in non-alcoholic fatty liver disease 62
Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea 62
Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. 59
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3 58
HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? 58
Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study 58
Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study 57
Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy 57
Viral hepatitis: Milestones, unresolved issues, and future goals 57
Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of Southern Italy in the province of Salerno 56
VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS 55
Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver 55
Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells 54
The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. 53
HCV-genotype 3h, a difficult-to-diagnose sub-genotype in the DAA era 53
Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle? 52
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 52
Chemical effect of bisphenol a on non-alcoholic fatty liver disease 52
Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program 52
Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. 50
Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study 50
NAFLD and extra-hepatic comorbidities: Current evidence on a multi-organ metabolic syndrome 48
Real‐Life Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Infected Patients with Chronic Kidney Disease 47
Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study 46
Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic 45
Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate-a pilot study 44
HCV point-of-care screening program and treatment options for people who use drugs in a metropolitan area of Southern Italy 44
Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study 43
THU-122-Sofosbuvir/velpatasvir ± ribavirin for retreatment of patients with chronic hepatitis C virus infection and advanced fibrosis failing to a previous DAA combination regimen 41
THU0289 PERSISTENCE OF CIRCULATING CRYOGLOBULINS AND RELATED SYMPTOMS AFTER HEPATITIS C VIRUS ERADICATION IN PATIENTS WITH MIXED CRYOGLOBULIN SYNDROME 41
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 41
THU-304-Modeling NAFLD-related disease progression among the PITER SVR12 cohort 41
Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System 41
Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis 39
A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 37
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 35
Solving the gap between HCV detection and treatment in prison. HCV-RNA testing and treatment in a cohort of new arriving convicts in Southern Italy 34
Nutrigenomics and nutrigenetics in metabolic-(Dysfunction) associated fatty liver disease: Novel insights and future perspectives 34
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 33
Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function 31
The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights 30
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 29
Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients 29
The role of resveratrol in liver disease: A comprehensive review from in vitro to clinical trials 29
Hepatitis C Virus Infection and Non-Hepatocellular Malignancies in the DAA Era: A Systematic Review and Meta-Analysis 28
Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study 27
Gut-Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers 25
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 24
PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial 24
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO) 24
From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention 23
Totale 6.414
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.706
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.706
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021562 28 35 44 19 58 38 65 13 39 12 81 130
2021/2022609 6 6 9 7 10 10 22 31 83 82 80 263
2022/2023918 102 72 54 110 99 189 3 67 135 5 60 22
2023/2024515 35 49 36 24 39 100 26 31 9 19 35 112
2024/20251.585 32 29 23 53 106 165 272 150 284 106 189 176
2025/202658 58 0 0 0 0 0 0 0 0 0 0 0
Totale 6.672